MEDICINE FOR ALL

Resources on COVID-19 vaccines development:

• WHO target product profile for COVID-19 vaccine
• Vaccine landscape
• Solidarity vaccine trial
• Access to COVID tools (ACT) Accelerator
• COVAX facility (WHO) Covax explained (GAVI) COPVAX (CEPI)
• WHO guidance on ethnics of vaccine allocation

Working together to deliver vaccine to all countries:

• The Access to Covid-19 Tools (ACT) Accelerator was launched in April 2020 to speed up development and delivery to countries of diagnostics, treatments and vaccines. It includes a health systems connector to support delivery of these resources to countries.
• WHO developed a framework for equitable  and affordable access to safe and effective vaccines.
• The COVAX facility is an umbrella mechanism through which demand and resources are pooled to support procurement of, and equitable access to, COVID-19 vaccines.
• The ACT Accelerator aims to deliver two billion vaccine doses for global needs by the end of 2021.
• Vaccine allocation will be driven by public health needs for priority groups, which may represent about 20% of the population, in the first year.
• Countries will be asked to develop vaccination plans.
• WHO recommends front-line personnel (such as health workers) and seniors be the first priority to receive vaccine

WHO Solidarity vaccine trial (Achieving rapid progress towards global objectives) :

• Evaluating several different candidate vaccines:

      Increasing the likelihood of finding several effective vaccines

• Expenditiously enrolling people at sites with high rates of COVID-19:

      Rapid accumulation of data to support rigorous evaluation

• Eliminating inefficiency of design and conduct of separate trials:

     Results within 3-6 months after each vaccine is ready for inclusion

• International collaboration and country commitment:

      Fosters international deployment with equity of access